Regorafenib: A Comprehensive Guide to Its Applications, Benefits, and Mechanism in Cancer Treatment
Explore the therapeutic potential of Regorafenib, a key player in advanced cancer management.
Get a Quote & SampleProduct Core Value
Regorafenib
Regorafenib is an oral multi-kinase inhibitor that targets angiogenic, stromal, and oncogenic receptor tyrosine kinases. It is crucial in treating advanced cancers, offering a new avenue for patients with limited options.
- Learn about the Regorafenib mechanism of action and how it disrupts cancer cell growth and survival pathways.
- Understand the efficacy of Regorafenib for metastatic colorectal cancer and its role in improving patient outcomes.
- Explore the benefits of Regorafenib in treating advanced gastrointestinal stromal tumors and its impact on progression-free survival.
- Discover the potential of Regorafenib for hepatocellular carcinoma management, offering hope for patients previously treated with sorafenib.
Product Advantages
Enhanced Efficacy
Regorafenib demonstrates significant benefits in extending overall survival for patients with metastatic colorectal cancer, highlighting its effectiveness in challenging cancer types.
Broad Therapeutic Spectrum
The drug's ability to target multiple receptor tyrosine kinases makes it a versatile option for treating advanced gastrointestinal stromal tumors and hepatocellular carcinoma, showcasing its broad application.
Potential Synergistic Effects
Research suggests that Regorafenib may work synergistically with omega-3 fatty acids, potentially enhancing its anti-cancer activity and offering new therapeutic strategies.
Key Applications
Metastatic Colorectal Cancer
Regorafenib has shown to improve overall survival for patients with metastatic colorectal cancer, representing a significant advancement in treatment options for this condition.
Advanced Gastrointestinal Stromal Tumours
For patients with advanced GIST that no longer respond to other treatments, Regorafenib offers a crucial option, delaying tumor growth and improving quality of life.
Advanced Hepatocellular Carcinoma
Regorafenib is approved for patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib, providing a vital next-step therapeutic strategy.
Oncology Research and Development
As a key pharmaceutical ingredient, Regorafenib is integral to ongoing oncology research and development, contributing to the advancement of cancer therapies.